AU Patent

AU2024200440A1 — Dual mode radiotracer and -therapeutics

Assigned to Technische Universitaet Muenchen · Expires 2024-02-08 · 2y expired

What this patent protects

The present invention relates to a ligand-SIFA-chelator conjugate, comprising, within in a single molecule three separate moieties: (a) one or more ligands which are capable of 5 binding to a disease-relevant target molecule, (b) a silicon-fluoride acceptor (SIFA) moiety which…

USPTO Abstract

The present invention relates to a ligand-SIFA-chelator conjugate, comprising, within in a single molecule three separate moieties: (a) one or more ligands which are capable of 5 binding to a disease-relevant target molecule, (b) a silicon-fluoride acceptor (SIFA) moiety which comprises a covalent bond between a silicon atom and a fluorine atom, and (c) one or more chelating groups, optionally containing a chelated nonradioactive or radioactive cation.

Drugs covered by this patent

Patent Metadata

Patent number
AU2024200440A1
Jurisdiction
AU
Classification
—
Expires
2024-02-08
Drug substance claim
No
Drug product claim
No
Assignee
Technische Universitaet Muenchen
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.